Protara Therapeutics, Inc. (TARA)
| Market Cap | 168.39M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -44.60M |
| Shares Out | 36.77M |
| EPS (ttm) | -2.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 112,992 |
| Open | 4.490 |
| Previous Close | 4.540 |
| Day's Range | 4.425 - 4.630 |
| 52-Week Range | 1.595 - 10.480 |
| Beta | 1.68 |
| Analysts | Strong Buy |
| Price Target | 22.67 (+394.98%) |
| Earnings Date | Mar 5, 2025 |
About TARA
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headqu... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for TARA stock is "Strong Buy." The 12-month stock price forecast is $22.67, which is an increase of 394.98% from the latest price.
News
Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results
TARA's leading candidate is TARA-002, which so far looks like a promising immune-stimulating therapy derived from OK-432 (Picibanil). Their recent Phase 2 ADVANCED-2 trial also showed favorable result...
Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
Data to be featured during oral presentation at the American Society for Parenteral and Enteral Nutrition 2025 Nutrition Science & Practice Conference Dosing of first patient in THRIVE-3 registrationa...
Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC; Announcement of initial data from 12-month evaluable patients expected by mid-2025 Dosing of first patient in...
Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...
Protara Highlights Recent Updates and Anticipated 2025 Milestones
Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC Completed approximately $100 million public offering, extending runway into 2027 Initial data from 12-month ev...
Protara Therapeutics: Rising From The Ashes
Protara Therapeutics' TARA-002 showed promising Phase 2 results, significantly improving its valuation and offering a strong risk-reward setup despite recent stock fluctuations. The company raised $10...
Protara Announces Closing of $100 Million Public Offering
NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...
Protara Therapeutics: Carving New Roads In Bladder Cancer
Protara Therapeutics' TARA-002 shows promising early data in bladder cancer, with a 72% complete response rate at 6 months in a small phase 2 trial. Financially, TARA has 7-8 quarters of funds, potent...
Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst
Initial data from the phase 2 ADVANCED-2 study, using TARA-002 for the treatment of patients with non-muscle invasive bladder cancer, is expected by mid-2025. The global bladder cancer market size is ...
Protara Announces Pricing of $100 Million Public Offering
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare dis...
Protara Announces Proposed Public Offering
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare dis...
Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday?
On Thursday, Protara Therapeutics Inc. TARA stock traded higher after the company revealed results from its ongoing Phase 2 open-label ADVANCED-2 trial.
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...
Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...
Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support
NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, toda...
Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, toda...
Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, toda...
Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today...
Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2026 Anticipated net proceeds, along with existing cash and cash equivalents, expected to e...
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, toda...
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, toda...
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, toda...